NCT02738775View on ClinicalTrials.gov

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

May 27, 2016

Primary Completion Date

September 27, 2017

Study Completion Date

August 13, 2018

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

Ublituximab

Administered as an IV infusion.

DRUG

Placebo

Trial Locations (12)

37922

TG Therapeutics Investigational Trial Site, Knoxville

40509

TG Therapeutics Investigational Trial Site, Lexington

43201

TG Therapeutics Investigational Trial Site, Columbus

44320

TG Therapeutics Investigational Trial Site, Akron

78258

TG Therapeutics Investigational Trial Site, San Antonio

78681

TG Therapeutics Investigational Trial Site, Round Rock

80045

TG Therapeutics Investigational Trial Site, Aurora

80528

TG Therapeutics Investigational Trial Site, Fort Collins

85018

TG Therapeutics Investigational Trial Site, Phoenix

90502

TG Therapeutics Investigational Trial Site, Torrance

91105

TG Therapeutics Investigational Trial Site, Pasadena

07666

TG Therapeutics Investigational Trial Site, Teaneck

All Listed Sponsors
lead

TG Therapeutics, Inc.

INDUSTRY

NCT02738775 - Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis | Biotech Hunter | Biotech Hunter